Pinnacle Private Wealth’s Lipocine LPCN Stock Holding History

Pinnacle Private Wealth’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-897	Closed	-$15K	–	326
2021 Q4	$15K	Buy	+897	New	+$16.7K	﹤0.01%	289

Other funds holding LPCN

AWA

Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Pinnacle Private Wealth's LPCN Position: Q1 2022 in Review

Pinnacle Private Wealth sold out of Lipocine (LPCN) in Q1 2022, closing a stake of 897 shares — an estimated $15K sold.

Pinnacle Private Wealth first reported a position in LPCN in Q4 2021 and held it in 1 quarter. The position peaked at $15K in Q4 2021. 44 funds tracked by Wall St. Rank hold LPCN as of Q1 2022.

Pinnacle Private Wealth reported no remaining Lipocine position as of Q1 2022 after selling out during the quarter.
Pinnacle Private Wealth sold 897 Lipocine shares in Q1 2022, an estimated $15K.
Pinnacle Private Wealth first reported a position in Lipocine in Q4 2021 and held it in 1 quarter.
Pinnacle Private Wealth's Lipocine position peaked at $15K in Q4 2021.
44 funds tracked by Wall St. Rank held Lipocine as of Q1 2022.

Based on Pinnacle Private Wealth's 13F filing for Q1 2022, filed 29 Apr 2022.